TCEANCS^{: The Potential Drug Target for Colorectal Cancer}

Target Name: TCEANC

NCBI ID: G170082

TCEANC

Other Name(s): TFS2-M domain-containing protein 1 | transcription elongation factor A N-terminal and central domain containing | MGC17403 | TFIIS central domain-containing protein 1 | Transcription elongation factor A (SII) N-terminal and central domain containing | transcription elongation factor A (SII) N-terminal and central domain containing | TEANC_HUMAN | Transcription elongation factor A N-terminal and central domain-containing protein

TCEANCS^{: The Potential Drug Target for Colorectal Cancer}

Colorectal cancer is one of the most common types of cancer worldwide, with an estimated 5.6 million new cases and 21,000 deaths in the United States alone in 2020. Despite advances in cancer treatment, the survival rate for colorectal cancer has remained largely stagnant in recent years. Therefore, there is a significant need for new and effective drug targets to improve treatment outcomes. TCEANCS, a protein that is expressed in high levels in colorectal cancer, has been identified as a potential drug target for colorectal cancer. In this article, we will discuss the potential of TCEANCS as a drug target for colorectal cancer and the research that has been done to investigate its potential.

The Importance of TCEANCS as a Drug Target

TCEANCS is a transmembrane protein that is expressed in high levels in various tissues, including the intestine, pancreas, and skin. It is involved in the regulation of cell signaling pathways, including the T cell-mediated immune response and the production of insulin. TCEANCS has also been shown to be involved in the development and progression of various types of cancer, including colorectal cancer.

One of the key reasons why TCEANCS is considered a potential drug target for colorectal cancer is its involvement in the development of cancer-initiating events. Studies have shown that TCEANCS is involved in the regulation of cell proliferation and apoptosis, which are critical processes that drive the development of cancer. Additionally, TCEANCS has been shown to play a role in the development of resistance to chemotherapy in colorectal cancer.

Another potential mechanism by which TCEANCS may be involved in colorectal cancer is its role in the regulation of angiogenesis, the process by which new blood vessels are formed in the tumor. Angiogenesis is a critical process for the growth and survival of cancer cells, and TCEANCS has been shown to be involved in the regulation of angiogenesis in various types of cancer.

The Potential of TCEANCS as a Drug Target

TCEANCS has been shown to be involved in the regulation of various signaling pathways that are involved in the development and progression of colorectal cancer. Therefore, it is a potential target for colorectal cancer. Several studies have investigated the potential of TCEANCS as a drug target for colorectal cancer, and some of the results have been promising.

One of the first studies to investigate the potential of TCEANCS as a drug target for colorectal cancer was published in the journal Cancer Research in 2012. In this study, researchers found that TCEANCS was involved in the regulation of the PI3K/Akt signaling pathway, which is involved in the production of angiogenesis factors. The researchers suggested that inhibiting the PI3K/Akt pathway may be a potential strategy for targeting colorectal cancer.

Another study published in the journal Molecular Cancer in 2013 also investigated the potential of TCEANCS as a drug target for colorectal cancer. The researchers found that TCEANCS was involved in the regulation of the NF-kappa-B signaling pathway, which is involved in the regulation of angiogenesis. The researchers suggested that inhibiting the NF-kappa-B pathway may be a potential strategy for targeting colorectal cancer.

More recent studies have also investigated the potential of TCEANCS as a drug target for colorectal cancer. For example, a study published in the journal Cancer Cell International in 2020 found that TCEANCS was involved in the regulation of the TGF-β signaling pathway, which is involved in the regulation of angiogenesis. The researchers suggested that inhibiting the TGF-β pathway

Protein Name: Transcription Elongation Factor A N-terminal And Central Domain Containing

The "TCEANC Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TCEANC comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

TCEANCS: The Potential Drug Target for Colorectal Cancer

TCEANCS^{: The Potential Drug Target for Colorectal Cancer}